Newormics is a developer of the first high-throughput, high-content screening platforms for use with in vivo small animal models as well as in vitro 3D tissue organoids. The company provides proprietary microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions.
At Newormics we are committed to empowering every scientist, research lab and drug discovery industry, to make discoveries faster with our modern and simple technology.
Newormics was co-founded in 2016 by Prof. Adela Ben-Yakar and Evan Hegarty and is a spinoff from the Ben-Yakar Lab in the Mechanical Engineering Department at the University of Texas at Austin.
A professor with dual appointments in Mechanical Engineering and Biomedical Engineering at The University of Texas at Austin, Dr Ben Yakar’s research focuses on the creation of imaging technologies and novel laser surgery with high precision. Educated at Stanford and the Technion in Israel, with post-doctoral study at Harvard, and using her NIH Director’s Transformative Research Award, Dr Ben Yakar began the research that has culminated in the launch of Newormics, LLC.
Evan Hegarty, co-founder, received his M.S. in Mechanical Engineering at The University of Texas at Austin while developing the technology and IP that lead to the launch of Newormics, LLC. As the Director of Manufacturing and Product development, and Principal Investigator of NIH SBIR grants at Newormics, Evan is responsible for development of all chip and system designs, creating production schedules, optimizing production methods, managing team members, identifying customer needs, developing future products, and reinforcing GLP and GMP.
Dr. Adam Laing is a molecular and cellular biologist educated at the University of Edinburgh, and leads the Research and Development activities of Newormics. He is responsible for testing and characterizing the new devices and imaging methods, and development of toxicology and drug screening assays in C. elegans as well as tissue organoids.
Shivang is a Biomedical Engineer, with sales & business acumen. He is heading our Sales & Marketing team and is responsible for customer relationship management, developing, maintaining and identifying KOLs, along with developing new product pricing strategies. He is also responsible for organizing marketing, media events, product promotional activities at conferences and B2B sales plans.
Dr. Lento is a serial COO/VPO executive for life science startups with broad skills in pharmaceuticals, medical devices, and diagnostics. With a unique background of equal parts government, public and private sector service, Dr. Lento holds a PhD in Biochemistry and additional credentials in Drug Evaluation, Pharmaceutical Sciences, and Corporate Governance.